XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common stock and additional paid-in capital
Retained earnings
Accumulated other comprehensive income (loss)
Beginning balance (in shares) at Dec. 31, 2020   10,950,289    
Balance at beginning of period at Dec. 31, 2020 $ 223,726 $ 65,395 $ 158,359 $ (28)
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]        
     Net income 8,922   8,922  
Net unrealized loss on securities available for sale, net of tax (4,790)     (4,790)
Net unrealized gain on securities transferred from available for sale to held to maturity, net of tax 9     9
Net unrealized gain on cash flow hedging derivative instruments, net of tax 3,469     3,469
Comprehensive income (loss) 7,610   8,922 (1,312)
Cash dividend declared (3,404)   (3,404)  
Equity compensation expense 288 $ 288    
Payment to repurchase common stock (in shares)   (8,557)    
Payment to repurchase common stock (218)   (218)  
Issuance of restricted stock (in shares)   34,689    
Issuance of restricted stock 0      
Proceeds from sale of common stock (in shares)   6,837    
Proceeds from sale of common stock $ 182 $ 182    
Ending balance (in shares) at Mar. 31, 2021 10,983,258 10,983,258    
Balance at end of period at Mar. 31, 2021 $ 228,184 $ 65,865 163,659 (1,340)
Beginning balance (in shares) at Dec. 31, 2021 10,998,765 10,998,765    
Balance at beginning of period at Dec. 31, 2021 $ 245,657 $ 66,940 180,417 (1,700)
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]        
     Net income 9,705   9,705  
Net unrealized loss on securities available for sale, net of tax (18,343)     (18,343)
Net unrealized gain on securities transferred from available for sale to held to maturity, net of tax 9     9
Net unrealized gain on cash flow hedging derivative instruments, net of tax 0      
Comprehensive income (loss) (8,629)   9,705 (18,334)
Cash dividend declared (3,528)   (3,528)  
Equity compensation expense 217 $ 217    
Payment to repurchase common stock (in shares)   (8,444)    
Payment to repurchase common stock (270)   (270)  
Issuance of restricted stock (in shares)   27,495    
Issuance of restricted stock 0      
Proceeds from sale of common stock (in shares)   6,270    
Proceeds from sale of common stock $ 199 $ 199    
Ending balance (in shares) at Mar. 31, 2022 11,024,086 11,024,086    
Balance at end of period at Mar. 31, 2022 $ 233,646 $ 67,356 $ 186,324 $ (20,034)